- Zacks•23 hours ago
Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
- American City Business Journals•yesterday
An experimental cancer drug developed by Cambridge-based Novartis Institutes for BioMedical Research has been shown to destroy tumors in mice and keep them from returning when used in combination with an approved treatment. Scientists sought to test the drug, called ABL001, in combination with an FDA-approved drug sold by Novartis (NVS) as Tasigna, as a potential treatment for chronic myeloid leukemia, or CML. The combination therapy was shown to quickly eradicate tumor cells in mice, and to keep them from returning for at least three months after treatment was stopped, according to the paper.
- Investor's Business Daily•yesterday
Analysts expected Novartis' heart drug to fail in a late-stage trial, an analyst said Wednesday after the firm fulfilled that prediction.
NVS.BA : Summary for NOVARTIS AG CEDEAR EACH REP 0.5 - Yahoo Finance
NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
|Day's Range||577.00 - 577.00|
|52 Week Range||566.85 - 585.00|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|